7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $11M | -$148M | 0.0% | -1329.4% | -121.2% | -84.5% | -$112M | — | $12M |
| 2024 | $10M | -$149M | 0.0% | -1667.2% | -58.9% | -47.6% | -$143M | — | $16M |
| 2023 | $34M | -$102M | 0.0% | -336.6% | -27.7% | -23.6% | -$105M | — | $51M |
| 2022 | $14M | -$99M | 0.0% | -768.2% | -33.0% | -26.6% | -$97M | — | $58M |
| 2021 | $10M | -$67M | 0.0% | -697.8% | -17.3% | -15.1% | -$35M | — | $240M |
| 2020 | $12M | -$34M | 0.0% | -292.2% | 146.4% | -95.2% | -$34M | — | $16M |
| 2019 | $6M | -$23M | 0.0% | -592.7% | -314.0% | — | -$33M | — | $41M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $1M | -$24M | 0.0% | -1690.4% | -24.8% | -17.0% | -$23M | — | $26M |
| Mar '26 | $2M | -$25M | 0.0% | -1096.4% | -24.6% | -16.8% | -$27M | — | $12M |
| Dec '25 | $4M | -$26M | 0.0% | -722.0% | -21.7% | -15.1% | -$21M | — | $12M |
| Sep '25 | $2M | -$28M | 0.0% | -1337.6% | -19.4% | -14.1% | -$25M | — | $11M |
| Jun '25 | $3M | -$54M | 0.0% | -1784.0% | -32.6% | -24.5% | -$29M | — | $25M |
| Mar '25 | $2M | -$40M | 0.0% | -1823.8% | -18.4% | -14.6% | -$38M | — | $29M |
| Dec '24 | $2M | -$35M | 0.0% | -1871.7% | -14.0% | -11.3% | -$36M | — | $16M |
| Sep '24 | $2M | -$35M | 0.0% | -1889.2% | -12.3% | -10.1% | -$33M | — | $32M |
| Jun '24 | $3M | -$38M | 0.0% | -1255.8% | -12.1% | -10.1% | -$35M | — | $38M |
| Mar '24 | $2M | -$41M | 0.0% | -1893.9% | -12.0% | -10.1% | -$39M | — | $49M |
| Dec '23 | $4M | -$35M | 0.0% | -1052.3% | -9.4% | -8.0% | -$24M | — | $51M |
| Sep '23 | $24M | -$10M | 0.0% | -61.8% | -2.5% | -2.2% | -$34M | — | $104M |
| Jun '23 | $4M | -$30M | 0.0% | -875.3% | -11.0% | -8.4% | -$18M | — | $66M |
| Mar '23 | $4M | -$28M | 0.0% | -888.5% | -10.1% | -8.1% | -$30M | — | $53M |
| Dec '22 | $4M | -$27M | 0.0% | -828.2% | -9.0% | -7.2% | -$27M | — | $58M |
| Sep '22 | $3M | -$27M | 0.0% | -803.4% | -8.2% | -6.7% | -$24M | — | $82M |
| Jun '22 | $4M | -$27M | 0.0% | -678.2% | -7.7% | -6.3% | -$24M | — | $112M |
| Mar '22 | $3M | -$19M | 0.0% | -782.8% | -5.1% | -4.3% | -$22M | — | $148M |
| Dec '21 | $3M | -$18M | 0.0% | -797.4% | -4.8% | -4.2% | -$22M | — | $240M |
| Sep '21 | $4M | -$21M | 0.0% | -468.1% | -5.2% | -4.5% | -$16M | — | $435M |
How the market has priced CRBU against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Caribou Biosciences, Inc.'s revenue has declined 2.0% per year. These are computed facts, not advice.
As of FY2025, Caribou Biosciences, Inc. reported — of total debt against $12M of cash.
In FY2025, gross margin was —, operating margin -1329.4%, and net margin -1327.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.